|Table of Contents|

The research progress of antibody-drug conjugate therapy in the malignant tumors of digestive system

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
916-922
Research Field:
Publishing date:

Info

Title:
The research progress of antibody-drug conjugate therapy in the malignant tumors of digestive system
Author(s):
CHENG Hao1; Yihebali?Chi2; SHI Susheng1
1.Department of Pathology；2.Department of Medical Oncology,National Cancer Center/National Clinical Research Center forCancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021，China.
Keywords:
antibody-drug conjugate; malignant tumors of digestive system; basic science; targeted therapy
PACS:
R730.53
DOI:
10.3969/j.issn.1672-4992.2022.05.034
Abstract:
Malignant tumors of digestive system present with relatively high morbidity and mortality.It is urgent to find novel and efficient treatment methods for patients who lack surgical indications or those who with poor radiotherapy and chemotherapy outcomes.Antibody-drug conjugates(ADCs)therapy has gradually become a research hot issue in recent years,with the advantages of both high selectivity of the antibody drug and the activity of cytotoxic drugs.ADCs therapy has made some achievements in the treatment of digestive system neoplasms,but it still needs to face many challenges.Here,we will give a brief review on the recent progress about ADCs in the treatment of tumors of digestive system.

References:

[1] 姚雪静.抗体药物偶联物的研究进展［J］.中外医学研究,2020,18(12):185-188. YAO XJ.Research progress of antibody drug conjugates［J］.Chinese and Foreign Medical Research,2020,18(12):185-188.
[2] RITCHIE M,TCHISTIAKOVA L,SCOTT N.Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates［J］.MAbs,2013,5(1):13-21.
[3] TANG HC,LIU Y,YU ZJ,et al.The analysis of key factors related to ADCs Structural design［J］.Front Pharmacol,2019,10:373.
[4] HAMBLETT KJ,SENTER PD,CHACE DF,et al.Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate［J］.Clin Cancer Res,2004,10(20):7063-7070.
[5] BANNAS P,HAMBACH J,KOCH-NOLTE F.Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics［J］.Front Immunol,2017,8:1603.
[6] SCHNEIDER EL,HEARN BR,PFAFF SJ,et al.Approach for half-life extension of small antibody fragments that does not affect tissue uptake［J］.Bioconjug Chem,2016,27(10):2534-2539.
[7] LOGANZO F,SUNG M,GERBER H.Mechanisms of resistance to antibody-drug conjugates［J］.Mol Cancer Ther,2016,15(12):2825-2834.
[8] ANDREEV J,THAMBI N,BAY AEP,et al.Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs［J］.Mol Cancer Ther,2017,16(4):681-693.
[9] RIOS-LUCI C,GARCIA-ALONSO S,DIAZ-RODRIGUEZ E,et al.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity［J］.Cancer Res,2017,77(17):4639-4651.
[10] BAUZON M,DRAKE PM,BARFIELD RM,et al.Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells［J］.Oncoimmunology,2019,8(4):e1565859.
[11] STROP P,TRAN TT,DORYWALSKA M,et al.RN927C,a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability,is highly efficacious in preclinical solid tumor models［J］.Mol Cancer Ther,2016,15(11):2698-2708.
[12] TUMEY LN.An overview of the current ADC discovery landscape［J］.Methods Mol Biol,2020,2078:1-22.
[13] BONO JSD,CONCIN N,HONG DS,et al.Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201):a first-in-human,multicentre,phase 1-2 trial［J］.Lancet Oncol,2019,20(3):383-393.
[14] SHENG Q,D’ALESSIO JA,MENEZES DL,et al.PCA062,a P-cadherin targeting antibody-drug conjugate,displays potent antitumor activity against P-cadherin-expressing malignancies［J］.Mol Cancer Ther,2021,20(7):1270-1282.
[15] THUSS-PATIENCE PC,SHAH MA,OHTSU A,et al.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY):an international randomised,open-label,adaptive,phase 2/3 study［J］.Lancet Oncol,2017,18(5):640-653.
[16] KOGANEMARU S,SHITARA K.Antibody-drug conjugates to treat gastric cancer［J］.Expert Opin Biol Ther,2021,21(7):923-930.
[17] SHITARA K,BANG YJ,IWASA S,et al.Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer［J］.N Engl J Med,2020,382(25):2419-2430.
[18] GONG JF,SHEN L,WANG WX,et al.Safety,pharmacokinetics and efficacy of RC48-ADC in a phase Ⅰ study in patients with HER2-overexpression advanced solid cancer［J］.J Clin Oncol,2018,36:e16059.
[19] SIENA S,BARTOLOMEO MD,RAGHAV K,et al.Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01):a multicentre,open-label,phase 2 trial［J］.Lancet Oncol,2021,22(6):779-789.
[20] GOLD P,SHUSTER J,FREEDMAN SO.Carcinoembryonic antigen (CEA) in clinical medicine:historical perspectives,pitfalls and projections［J］.Cancer,1978,42(3 Suppl):1399-1405.
[21] DOTAN E,COHEN SJ,STARODUB AN,et al.Phase Ⅰ/Ⅱ trial of labetuzumab govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in patients with refractory or relapsing metastatic colorectal cancer［J］.J Clin Oncol,2017,35(29):3338-3346.
[22] KOGANEMARU S,KUBOKI Y,KOGA Y,et al.U3-1402,a novel HER3-targeting antibody-drug conjugate,for the treatment of colorectal cancer［J］.Mol Cancer Ther,2019,18(11):2043-2050.
[23] RAGHAV KPS,YOSHINO T,TANIGUCHI H,et al.An open-label,phase II study of patritumab deruxtecan (HER3-DXd,U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)［J］.J Clin Oncol,2021,39(3):TPS157.
[24] CAPURRO M,WANLESS IR,SHERMAN M,et al.Glypican-3:a novel serum and histochemical marker for hepatocellular carcinoma［J］.Gastroenterology,2003,125(1):89-97.
[25] FU Y,URBAN DJ,NANI RR,et al.Glypican-3-specific antibody drug conjugates targeting hepatocellular carcinoma［J］.Hepatology,2019,70(2):563-576.
[26] LU Y,DAND QH,BO Y,et al.The expression of CLDN6 in hepatocellular carcinoma tissue and the effects of CLDN6 on biological phenotypes of hepatocellular carcinoma cells［J］.J Cancer,2021,12(18):5454-5463.
[27] KONG FN LI GM,TANG YQ,et al.Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate［J］.Sci Transl Med,2021,13(579):eabb6282.
[28] HUANG LR,HSU HC.Cloning and expression of CD24 gene in human hepatocellular carcinoma:a potential early tumor marker gene correlates with p53 mutation and tumor differentiation［J］.Cancer Res,1995,55(20):4717-4721.
[29] MA ZX,HE H,SUN FM,et al.Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo［J］.J Cancer Res Clin Onocl,2017,143(10):1929-1940.
[30] SUN FM,WANG T,JIANG JH,et al.Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design［J］.Oncotarget,2017,8(31):51238-51252.
[31] ROLAND CL,HARKEN AH,SARR MG,et al.ICAM-1 expression determines malignant potential of cancer［J］.Surgery,2007,141(6):705-707.
[32] HUANG J,AGOSTON AT,GUO P,et al.A rationally designed ICAM1 antibody drug conjugate for pancreatic cancer［J］.Adv Sci (Weinh),2020,7(24):2002852.
[33] NISHIGAKI T,TAKAHASHI T,SERADA S,et al.Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer［J］.Br J Cancer,2020,122(9):1333-1341.
[34] CARDILLO TM,GOVINDAN SV,SHARKEY RM,et al.Sacituzumab Govitecan (IMMU-132),an anti-Trop-2/SN-38 antibody-drug conjugate:characterization and efficacy in pancreatic,gastric,and other cancers［J］.Bioconjug Chem,2015,26(5):919-931.
[35] CAZES A,BETANCOURT O,ESPARZA E,et al.A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer［J］.Clin Cancer Res,2021,27(7):2100-2110.
[36] JIN YB,ZHANG ZH,ZOU SY,et al.A novel c-MET-targeting antibody-drug conjugate for pancreatic cancer［J］.Front Oncol,2021,11:634881.

Memo

Memo:
-
Last Update: 2022-01-27